Suppr超能文献

细胞外HSP90通过双功能小分子促进细胞外和膜蛋白的降解

Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules.

作者信息

Zhang Dongli, Li Jie, Liang Yaqi, Li Tao, Ji Ming, Liu Xinmin, Li Wenxin, Chen Pengxiao, Zhang Jiamin, Yang Zhengduo, Wang Lulu, Chen He

机构信息

The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, Department of Chemical Biology, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.

Department of Medicinal Chemistry, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.

出版信息

J Med Chem. 2025 Jun 26;68(12):12641-12657. doi: 10.1021/acs.jmedchem.5c00379. Epub 2025 Jun 11.

Abstract

Lysosome-targeting chimeras represent a promising strategy for degrading extracellular and membrane proteins via the lysosomal pathway, but the available receptor options remain limited. Herein, we report a novel strategy utilizing extracellular heat shock protein 90 (eHSP90) to facilitate lysosomal degradation of target proteins through bifunctional small molecules, termed extracellular heat shock protein 90-targeting chimeras (eHSPTACs). By connecting an HSP90 ligand to a target protein ligand, eHSPTACs effectively induced the internalization and subsequent lysosomal degradation of extracellular Alexa Fluor 488-labeled α-DNP antibody and membrane programmed cell death-ligand 1 (PD-L1). Notably, selectively degraded membrane PD-L1 in tumor cells over normal cells, leveraging the elevated expression of eHSP90 in cancer cells. Moreover, demonstrated robust in vivo degradation of membrane PD-L1 and significant tumor growth suppression in the B16F10 syngeneic mouse model. Overall, eHSPTACs offer a general platform for tumor-selective degradation of extracellular and membrane proteins, providing a new therapeutic avenue.

摘要

溶酶体靶向嵌合体是一种通过溶酶体途径降解细胞外和膜蛋白的有前景的策略,但可用的受体选择仍然有限。在此,我们报告了一种利用细胞外热休克蛋白90(eHSP90)通过双功能小分子促进靶蛋白溶酶体降解的新策略,称为细胞外热休克蛋白90靶向嵌合体(eHSPTACs)。通过将HSP90配体与靶蛋白配体连接,eHSPTACs有效地诱导了细胞外Alexa Fluor 488标记的α-DNP抗体和膜程序性细胞死亡配体1(PD-L1)的内化及随后的溶酶体降解。值得注意的是,利用癌细胞中eHSP90的高表达,eHSPTACs在肿瘤细胞中比正常细胞更能选择性地降解膜PD-L1。此外,在B16F10同基因小鼠模型中,eHSPTACs证明了对膜PD-L1有强大的体内降解作用,并显著抑制肿瘤生长。总体而言,eHSPTACs为细胞外和膜蛋白的肿瘤选择性降解提供了一个通用平台,开辟了一条新的治疗途径。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验